Cosyntropin
Cortrosyn (cosyntropin) is a protein pharmaceutical. Cosyntropin was first approved as Cortrosyn on 1982-01-01. The pharmaceutical is active against adrenocorticotropic hormone receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Cortrosyn (generic drugs available since 2009-12-17)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cosyntropin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CORTROSYN | Amphastar Pharmaceuticals | N-016750 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cortrosyn | New Drug Application | 2022-12-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0834 | Injection, cosyntropin, 0.25 mg |
Clinical
Clinical Trials
92 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | 1 | 5 | 2 | 9 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | 5 | 2 | 9 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 2 | 2 | 3 | — | 5 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | 1 | 3 | 1 | 5 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | — | 4 | — | 4 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | — | 1 | — | 1 | 1 | 3 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | — | — | 2 | 1 | 3 |
| Posterior uveitis | D015866 | EFO_1001119 | — | — | — | 3 | — | 3 | |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | — | 1 | 2 | — | 3 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | 1 | — | 2 | — | 3 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 2 | 1 | — | — | 2 |
| Hypercalcemia | D006934 | E83.52 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polymyositis | D017285 | EFO_0003063 | M33.2 | — | 1 | — | — | 1 | 2 |
| Infantile spasms | D013036 | EFO_1000643 | G40.82 | — | 1 | — | — | 1 | 2 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | — | — | — | 1 | |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | — | 1 |
| Chronic inflammatory demyelinating polyradiculoneuropathy | D020277 | EFO_1000868 | G61.81 | — | 1 | — | — | — | 1 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
| Glomerulonephritis | D005921 | N05 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
| Proliferative vitreoretinopathy | D018630 | EFO_1001129 | 1 | — | — | — | — | 1 | |
| Optic neuritis | D009902 | EFO_0007405 | H46 | 1 | — | — | — | — | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 1 | 1 |
| Gout | D006073 | EFO_0004274 | M10 | — | — | — | — | 1 | 1 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 1 | 1 |
| Cocaine-related disorders | D019970 | F14 | — | — | — | — | 1 | 1 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 1 | 1 |
| Abdominal aortic aneurysm | D017544 | EFO_0004214 | — | — | — | — | 1 | 1 | |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | — | — | — | 1 | 1 |
| Septic shock | D012772 | A48.3 | — | — | — | — | 1 | 1 | |
| Adrenal insufficiency | D000309 | — | — | — | — | 1 | 1 | ||
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | COSYNTROPIN |
| INN | tetracosactide |
| Description | Cortrosyn, Cosyntropin (cosyntropin) is a protein pharmaceutical. Cosyntropin was first approved as Cortrosyn on 1982-01-01. The pharmaceutical is active against adrenocorticotropic hormone receptor. |
| Classification | Protein |
| Drug class | tricyclic compounds; atropine derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 16960-16-0 |
| RxCUI | 2890 |
| ChEMBL ID | CHEMBL2103784 |
| ChEBI ID | 3901 |
| PubChem CID | 16129674 |
| DrugBank | DB01284 |
| UNII ID | 72YY86EA29 (ChemIDplus, GSRS) |
Target
Agency Approved
MC2R
MC2R
Organism
Homo sapiens
Gene name
MC2R
Gene synonyms
ACTHR
NCBI Gene ID
Protein name
adrenocorticotropic hormone receptor
Protein synonyms
ACTH receptor, Adrenocorticotropin receptor, corticotropin receptor, MC2 receptor, MC2-R, melanocortin 2 receptor (adrenocorticotropic hormone), Melanocortin receptor 2
Uniprot ID
Mouse ortholog
Mc2r (17200)
adrenocorticotropic hormone receptor (Q64326)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,120 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,296 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more